236 related articles for article (PubMed ID: 23664673)
1. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Masi G; Pfanner C; Brovedani P
J Psychiatr Res; 2013 Aug; 47(8):1007-12. PubMed ID: 23664673
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
Masi G; Pfanner C; Millepiedi S; Berloffa S
J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
[TBL] [Abstract][Full Text] [Related]
3. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.
Akyol Ardic U; Ercan ES; Kutlu A; Yuce D; Ipci M; Inci SB
Child Psychiatry Hum Dev; 2017 Oct; 48(5):699-704. PubMed ID: 27812841
[TBL] [Abstract][Full Text] [Related]
6. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Veale D; Miles S; Smallcombe N; Ghezai H; Goldacre B; Hodsoll J
BMC Psychiatry; 2014 Nov; 14():317. PubMed ID: 25432131
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
9. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
Ak M; Bulut SD; Bozkurt A; Ozsahin A
Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
[TBL] [Abstract][Full Text] [Related]
12. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China.
Cui YH; Zheng Y; Yang YP; Liu J; Li J
J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):291-8. PubMed ID: 20807067
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
15. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
Sayyah M; Sayyah M; Boostani H; Ghaffari SM; Hoseini A
Depress Anxiety; 2012 Oct; 29(10):850-4. PubMed ID: 22933237
[TBL] [Abstract][Full Text] [Related]
16. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
de Oliveira MVS; de Barros PMF; de Mathis MA; Boavista R; Chacon P; Echevarria MAN; Ferrão YA; Vattimo EFQ; Lopes AC; Torres AR; Diniz JB; Fontenelle LF; Rosário MCD; Shavitt RG; Miguel EC; da Silva RMF; Costa DLDC
Braz J Psychiatry; 2023 May; 45(2):146-161. PubMed ID: 36749887
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts.
Budman C; Coffey BJ; Shechter R; Schrock M; Wieland N; Spirgel A; Simon E
J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):509-15. PubMed ID: 18928415
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.
Masi G; Cosenza A; Millepiedi S; Muratori F; Pari C; Salvadori F
CNS Drugs; 2009; 23(6):511-21. PubMed ID: 19480469
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Brakoulias V; Stockings E
Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]